Patient Profiling & Provider Feedback to Reduce Adverse Drug Events

Status Completed

Clinical Trial Summary

Adverse drug events (ADE) present a unique focus for error reduction. Computerized provider order entry, with embedded clinical decision support, has great promise in reducing medication errors but preventable adverse drug events may still occur despite such systems.

Clinical Trial Description

Background:

Adverse drug events (ADE) present a unique focus for error reduction. Computerized provider order entry, with embedded clinical decision support, has great promise in reducing medication errors but preventable adverse drug events may still occur despite such systems.

Objectives:

The purpose of the study was to evaluate whether adding medication profiling (by using a retrospective drug utilization review program) to computerized provider order entry with embedded order checks (drug alerts) reduces the incidence of adverse drug events.

Methods:

Medication profiles mainly focused on possible drug-drug and drug-disease interactions, with some drug duplications. To do the medication profiles we licensed a proprietary computerized retrospective drug utilization review system. We randomly assigned over 900 patients to Usual Care or Provider Feedback. For patients in the latter group, selected providers were contacted by letter with pertinent information; electronic mail was used for follow-up contact. Clinical and other relevant data was retrospectively abstracted from the medical records for up to one year from the last medication profile for all patients. This was done by a pharmacist reviewer, using a study-derived instrument, and blinded to patient assignment. ADE incidence is the primary outcome of interest, with other outcomes such as ADE severity and preventability also assessed. We also developed and implemented provider surveys in pre- and post-profiling periods.

Status:

Pre and post survey results published. Adjunct study on clinical actions as a result of drug alerts published. Main study (profiling): manuscript in proces. ;

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind

Related Conditions & MeSH terms

Adverse Drug Events
Drug-Related Side Effects and Adverse Reactions

Clinical Trial Details

NCT number	NCT00013143
Study type	Interventional
Source	VA Office of Research and Development
Contact
Status	Completed
Phase	N/A
Start date	June 2001
Completion date	January 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239237` - Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Completed	`NCT02191358` - YouScript IMPACT Registry	N/A
Completed	`NCT01179867` - Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge	N/A
Completed	`NCT02059044` - Information Systems-enabled Outreach Program for Adverse Drug Events	N/A
Completed	`NCT01164137` - Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care	N/A
Completed	`NCT02482025` - The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial	N/A
Completed	`NCT04692220` - Drug-Related Problems : Focus on Age and Diabetes
Completed	`NCT02378220` - Pharmacogenetic Testing Among Home Health Patients	N/A
Completed	`NCT01337063` - Multi-Center Medication Reconciliation Quality Improvement Study	N/A
Completed	`NCT02593916` - Response to Medication Registry
Withdrawn	`NCT00606606` - Reducing Adverse Drug Events in the Nursing Home	N/A
Completed	`NCT02026453` - Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy	N/A
Completed	`NCT02805270` - Impact of Medication Reconciliation Intervention on the Rate of Preventable Adverse Drug Events (ADEs) and Healthcare Utilization	N/A
Completed	`NCT01764204` - Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years	N/A
Completed	`NCT01531088` - Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes	N/A
Completed	`NCT02122965` - The Effect of Medication Review in High-risk Emergency Department Patients	N/A
Completed	`NCT00780572` - Implementation of Real-time ADE Surveillance and Decision Support	N/A
Completed	`NCT01091038` - Improving Safety by Basic Computerizing Outpatient Prescribing	Phase 2/Phase 3
Recruiting	`NCT04479553` - Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
Active, not recruiting	`NCT00740675` - Ambulatory Medication Reconciliation Following Hospital Discharge	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Patient Profiling and Provider Feedback to Reduce Adverse Drug Events

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms